Jennifer Bath, Ph.D.

Chief Executive Officer and President

Jennifer holds a Ph.D. in Cellular and Molecular biology from North Dakota State University, and a Bachelor’s degree in Biology, with an emphasis on human genetics, from the University of Kansas. She began her career in academia, and moved into industry after a 15-year appointment as an Associate Professor of Cellular and Molecular Biology at Concordia College, Moorhead, Minnesota. She was the Founder and Executive Director of the Concordia College Global Vaccine Institute; whose mission is to prevent and treat neglected tropical diseases. Jennifer has broad experience in vaccine and therapeutic design, development and testing.

Dr. Bath served many guidance roles in industry including advising on the Economic Development Corporation’s Strategic Planning Initiatives, consulting biotechnology and pharmaceutical companies on strategic and operational business practices, and providing governance for workshops in technology entrepreneurship. She has established relationships with leaders in the fields of therapeutics and vaccinology, enhancing collaborative developments and partnerships in discovery.

Jennifer served in an executive role at Aldevron, LLC, as the Global Director of Client Relations, where she held both strategic and technical roles. She headed the global sales and client relations teams, and defined business strategies by applying knowledge based on the science, technology and the market. In addition, she served as a key technical specialist, particularly for therapeutic antibody discovery, and was responsible for retention and growth of the existing client base through individual efforts and efforts of the management team to deliver profitable, quality services.

Teri Otto

General Manager

Teri Otto joined ImmunoPrecise in 1997 as a co-op student and continued as a fulltime employee upon graduation in 2000. She began as a technician and animal care manager. She has been a key part of developing ImmunoPrecise’s successful laboratory operations and antibody engineering capabilities, particularly in the area of mouse hybridomas. Ms. Otto served 17 years in directing laboratory operations and project management before leading IPA’s Marketing and Sales team. She now serves as the General Manager of ImmunoPrecise Antibodies’ Victoria site, where she oversees all business units. Ms. Otto holds a B.Sc. (with distinction) from University of Victoria in Microbiology and Associate Degrees in Psychology, Biochemistry, and Applied Chemistry from Camosun College in Victoria, BC.

Deanna Dryhurst

Chief Scientific Officer

Dr. Dryhurst joined ImmunoPrecise in 2010. She received an NSERC Industrial Research and Development Postdoctoral Fellowship to work on a platform for rabbit monoclonal antibody development at ImmunoPrecise Antibodies where she was key in the development of IPA’s B cell technology. Rabbit monoclonal antibodies are now a key part of what ImmunoPrecise provides to its clients. She is currently in charge of R&D at ImmunoPrecise where she is responsible for the prioritization of research projects, alignment with corporate strategy, and developing new product introductions. She received her B.Sc. in Biology, and her Ph.D. in Biochemistry and Molecular Biology from the University of Victoria.

Chip Wheelock

Chief Technology Officer

As the Chief Technology Officer of ImmunoPrecise Antibodies, Chip Wheelock is responsible for overseeing all information technology aspects of ImmunoPrecise Antibodies.  Mr. Wheelock works closely with the other members of the Executive Management team and unit business leaders to grow the company through the use of software and technology services. Using an active and practical approach, Mr. Wheelock directs all employees in the Information Technology departments to attain the company’s strategic goals and establishes the company’s information technology strategic plan.

Mr. Wheelock oversees all aspects of Information Technology where he provides leadership for continuous innovation of a wide array of technological systems across all of IPA’s businesses. He works closely with the individual business leaders to ensure that the technology and collaboration systems increase efficiencies and focuses on creating a competitive advantage through the innovative use of technology.  Mr. Wheelock brings a diverse background to IPA, he has held leadership positions within the software development and services industries over the past 25 years encompassing global ERP deployments, cloud transformations and building strategic line of business applications.  Mr. Wheelock’s experience includes 16 years at Microsoft in various roles, most recently as a Senior Global Technical Account Manager, where he drove both strategic and technical initiatives for many large organizations. Mr. Wheelock holds a Bachelor’s degree from the University of Kansas along with several industry and project management certifications.

Robert Beecroft

Founder and Director

Robert Beecroft founded ImmunoPrecise in 1989 and previously served as its Chief Executive Officer and President. Mr. Beecroft has over 25 years’ experience in the development of innovative and proprietary methods for the production of monoclonal and polyclonal antibodies and peptides. Mr. Beecroft has a B.Sc. in Microbiology from University of Victoria and has been involved in over 15 Research Projects over the course of the last 25 years and been an instructor for graduate students at the University of Victoria on the use and production of monoclonal antibodies for over 13 years.  In 2015, Mr. Beecroft was the recipient of the UVic Distinguished Alumni Award for the Faculty of Science, in recognition for being the Founder of ImmunoPrecise Antibodies Ltd.

Kari Graber

Director of Global Project Management

Kari Graber serves as the Director of Global Project Management for ImmunoPrecise Antibodies and is responsible for the overall leadership and implementation of the Project Management program throughout IPA’s global family of companies. She has over 20 years of experience in developing, implementing and directing laboratory operations, quality assurance, regulatory compliance, and supply chain management programs for various food manufacturers and spent five years as Sales and Technical Director for a pasteurization/sterilization technology and equipment supplier. Prior to joining ImmunoPrecise, Ms. Graber served at Aldevron LLC where she held a client relations management role for their antibody services platform. Kari holds a Bachelor of Science in Food Science & Technology with a Minor in Microbiology from North Dakota State University.

Reg Beniac

Chief Operating Officer

As the COO of ImmunoPrecise Antibodies, Reg Beniac is responsible for running all facets of business operations, including onboarding new acquisitions into the IPA family of companies. Reg works closely with the individual business unit leaders and teams to ensure that each unit continues to deliver outstanding service to a larger customer base. He has a proven executive management track record with over 20 years of international experience leading teams in the design, building, and implementation of: business operations, sales, accounting, and financial systems. Reg’s experience includes key management consulting and business building roles at the Business Development Bank of Canada and his own company, as well as being the key architect in the design and implementation a US Banking and Capital Markets regulatory compliance management system. Reg is an Adjunct Lecturer at the Gustavson School of Business (University of Victoria, Victoria British Columbia) and a graduate supervisor for the Smith School of Business (Queen’s University, Kingston Ontario). Reg earned a degree in Economics from the University of Victoria, an MBA from the Smith School of Business, and is a Chartered Professional Accountant.